121 related articles for article (PubMed ID: 38536906)
1. Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia.
De Coninck S; Roels J; Lintermans B; T'Sas S; Taghon T; Curtis DJ; Pieters T; Goossens S; Van Vlierberghe P
Blood Adv; 2024 Mar; ():. PubMed ID: 38536906
[TBL] [Abstract][Full Text] [Related]
2. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
3. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
[TBL] [Abstract][Full Text] [Related]
5. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.
Di Giacomo D; La Starza R; Gorello P; Pellanera F; Kalender Atak Z; De Keersmaecker K; Pierini V; Harrison CJ; Arniani S; Moretti M; Testoni N; De Santis G; Roti G; Matteucci C; Bassan R; Vandenberghe P; Aerts S; Cools J; Bornhauser B; Bourquin JP; Piazza R; Mecucci C
Blood; 2021 Sep; 138(9):773-784. PubMed ID: 33876209
[TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
7. Effects of hypoxia on DNA hydroxymethylase Tet methylcytosine dioxygenase 2 in a KG-1 human acute myeloid leukemia cell line and its mechanism.
He P; Lei J; Zou LX; Zhou GZ; Peng L; Deng Q; Liu XL
Oncol Lett; 2021 Oct; 22(4):692. PubMed ID: 34457047
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
9. microRNA-22 can regulate expression of the long non-coding RNA MEG3 in acute myeloid leukemia.
Yao H; Sun P; Duan M; Lin L; Pan Y; Wu C; Fu X; Wang H; Guo L; Jin T; Ding Y
Oncotarget; 2017 Sep; 8(39):65211-65217. PubMed ID: 29029424
[TBL] [Abstract][Full Text] [Related]
10. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
11. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
[TBL] [Abstract][Full Text] [Related]
12. B-cell tumor development in
Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
[TBL] [Abstract][Full Text] [Related]
13. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia.
Bensberg M; Rundquist O; Selimović A; Lagerwall C; Benson M; Gustafsson M; Vogt H; Lentini A; Nestor CE
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34413196
[TBL] [Abstract][Full Text] [Related]
14. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
15. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
16. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
17. Monoallelic
Veiga DFT; Tremblay M; Gerby B; Herblot S; Haman A; Gendron P; Lemieux S; Zúñiga-Pflücker JC; Hébert J; Cohen JP; Hoang T
Front Immunol; 2022; 13():867443. PubMed ID: 35401501
[TBL] [Abstract][Full Text] [Related]
18. Cell of origin in radiation-induced premalignant thymocytes with differentiation capability in mice conditionally losing one Bcl11b allele.
Go R; Hirose S; Katsuragi Y; Obata M; Abe M; Mishima Y; Sakimura K; Kominami R
Cancer Sci; 2013 Aug; 104(8):1009-16. PubMed ID: 23663453
[TBL] [Abstract][Full Text] [Related]
19. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid.
Cai Z; Lu X; Zhang C; Nelanuthala S; Aguilera F; Hadley A; Ramdas B; Fang F; Nephew K; Kotzin JJ; Williams A; Henao-Mejia J; Haneline L; Kapur R
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33090974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
